ACS Medicinal Chemistry Letters
Scientists are reporting development and initial laboratory tests of an imaging agent that shows promise for detecting the tell-tale signs of Alzheimer’s disease (AD) in the brain — signs that now can’t confirm a diagnosis until after patients have died. Their report appears in the journal ACS Medicinal Chemistry Letters.
